继吡格列酮后，全球迎来首个非TZD结构的PPAR全激动剂。10月19日，据国家药品监督管理局（NMPA）官网最新公示，微芯生物的1类新药西格列他钠（双洛平）正式获批，单药适用于配合饮食控制和运动，改善成人2型糖尿病患者的血糖控制。
全球首个！微芯生物PPAR全激动剂「西格列他钠」正式获NMPA批准上市
Source：
Release Time：2021-10-20
The number of readers：673
Previous：
困扰全球超过1.3亿女性的疾病 有望迎来首款FDA批准疗法
Related Tags
Latest News
- 1、 Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease
- 2、 Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab
- 3、 Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting
- 4、 Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
- 5、 Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
Related Products
Hot Tags
Inquiry
Fill in related informations ;please!
- Please fill in product name !
- CAS
- Please fill in your company information correctly!
- Please fill in liaison information correctly!
- Please fill in your telephone number correctly!
- Please fill in your email correctly!
- Please describe the problem of products!